THERAPEUTICS INC Q has a total of 13 patent applications. Its first patent ever was published in 2004. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology, pharmaceuticals and environmental technology are MAO YUMIN, PLACHTER BODO and KINGSMAN ALAN JOHN.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Israel | 1 | |
#6 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Environmental technology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds | |
#5 | Climate change mitigation in goods production | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Ramaswami Mani | 4 |
#2 | Eppstein Deborah A | 4 |
#3 | Rao Mahendra S | 4 |
#4 | Campanelli James T | 4 |
#5 | Zeng Xianmin | 4 |
#6 | Sandrock Robert | 3 |
#7 | Robert Sandrock | 1 |
Publication | Filing date | Title |
---|---|---|
CN107429261A | Produce single or multiplexed reporters method and compositions rapidly in cell | |
CN107532142A | Mescenchymal stem cell is transformed using homologous recombination | |
WO2011059952A1 | Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells | |
KR20060123702A | Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders |